68 results
8-K
EX-99.1
OVID
Ovid Therapeutics Inc
14 May 24
Ovid Therapeutics Reports Business Updates and First Quarter 2024 Financial Results
8:03am
or best-in-class neurotherapeutics. The mechanisms of action in Ovid’s pipeline programs address biological targets implicated in neuronal hyperexcitability … business development targets or strategic partners, to enter into strategic transactions on favorable terms, or to consummate and realize the benefits
8-K
EX-99.1
OVID
Ovid Therapeutics Inc
8 Mar 24
Ovid Therapeutics Reports Business Updates, Fourth Quarter and Full Year 2023 Financial Results
8:20am
business development targets or strategic partners, to enter into strategic transactions on favorable terms, or to consummate and realize the benefits
424B5
OVID
Ovid Therapeutics Inc
15 Nov 23
Prospectus supplement for primary offering
4:11pm
medicines. Our knowledge of the underlying biologic targets driving hyperexcitability and the pathology of refractory epilepsies has produced clinical-stage
8-K
EX-99.1
y4r3r5b9
3 Nov 23
Ovid Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Updates
8:10am
8-K
EX-99.1
o9fuy
18 Oct 23
Ligand will receive 13% of all soticlestat royalties and milestone payments owed to Ovid
8:04am
8-K
pg1oz
18 Oct 23
Ligand will receive 13% of all soticlestat royalties and milestone payments owed to Ovid
8:04am
8-K
EX-99.1
2kz3eic8hpams6xm5
2 Oct 23
Dawn of the neurotherapeutics era Dr. Jeremy Levin CEO & Chairman
12:15pm
8-K
EX-99.1
uexkus6zkuqb46urse
4 Aug 23
Ovid Therapeutics Reports Second Quarter 2023 Financial Results and Corporate Updates
9:10am
8-K
EX-99.1
h3d18s5 bajct
5 May 23
Ovid Therapeutics Reports First Quarter 2023 Financial Results and Corporate Updates
8:16am
8-K
EX-99.1
flg694rl8h3p6
8 Nov 22
Ovid Therapeutics Reports Third Quarter 2022 Financial Results and Corporate Highlights
8:41am
8-K
EX-99.1
qyaql 6ehg
9 Aug 22
Ovid Therapeutics Reports Second Quarter 2022 Financial Results and Corporate Highlights
8:18am